Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12426518 | 0.85 | CXCR4 (0.49) | CXCR4MEN1KMT2AMLLT1 | |
| SCHEMBL2201355 | 0.83 | KMT2A (0.45) | CXCR4MEN1KMT2ALMNA | |
| SCHEMBL2204094 | 0.81 | CXCR4 (0.57) | CXCR4TSHRBCHE | |
| SCHEMBL2201588 | 0.81 | CXCR4 (0.52) | CXCR4MEN1KMT2A | |
| SCHEMBL2202944 | 0.78 | CXCR4 (0.40) | CXCR4TSHRLMNAPKMNPSR1 | |
| SCHEMBL1206752 | 0.78 | MEN1 (0.45) | CXCR4MEN1KMT2A | |
| SCHEMBL1638428 | 0.78 | DRD4 (0.52) | CXCR4MEN1KMT2A | |
| SCHEMBL2201590 | 0.75 | CXCR4 (0.46) | CXCR4MEN1KMT2A | |
| SCHEMBL1637333 | 0.75 | CXCR4 (0.61) | CXCR4MEN1KMT2ALMNANPSR1 | |
| SCHEMBL12416698 | 0.74 | CXCR4 (0.58) | CXCR4MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977512-B2 | Amine derivative, and production method and use thereof | KUREHA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | KUREHA CORPORATION | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | BCAT2, BCAT1, MRPL9 | CXCR4 2546/4885MEN1 1672/4885KMT2A 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.